Cardiorenometabolic syndrome stage 2–3 in self-independent elderly patients

Objective. To characterize the clinical and laboratory characteristics of patients aged 60–74 years with stage 2–3 cardiorenometabolic syndrome (CKM) and a retrospective assessment of 15-year follow-up.
Materials and methods. Anthropometric, laboratory and instrumental examination data of patients contained in the medical records of 73 overweight/obese patients with arterial hypertension aged 60–74 years without clinical cardiovascular clinical diseases (CKM stage 2 and 3).
Results and discussion. The incidence of diabetes/prediabetes was 20.5 % (95 % CI (12.9–31.2)), metabolic syndrome was 64.4 % (95 % CI (52.9–74.4)). The TyG index in patients with metabolic syndrome ranged from 7.78 to 11.83, median (Me) and interquartile interval [Q1; Q3] were 8.84 and [8.53; 9.13] and exceeded the results of patients without metabolic syndrome (Mann – Whitney test z = 4.018413, p = 0.0001). In 44.9 % of patients, the serum uric acid level was equal to or greater than 360 μmol/L. The growth rate over 15 years was 106 % for obesity (6 % increase), 202 % for hypertension (102 % increase), and 500 % for diabetes mellitus (400 % increase). Over a 10-year period, the structure CKD-EPI ≥ 60/˂ 60 mL/min/1,73м² ranged from 80/20 % to 65/35 %.
Conclusion. The study gives an idea of the frequency and 15-year dynamics without progression to CKM stage 4 in the elderly under the conditions of observation by the media service of an industrial enterprise.

1. Rangaswami J., Bhalla V., Blair J.E.A., et al. Cardiorenal syndrome: classification, pathophysiology, diagnosis, and treatment strategies. Circulation. 2019; 139(16). doi: 10.1161/CIR.0000000000000664.

2. Ndumele C.E., Neeland I.J., Tuttle K.R., et al. A synopsis of the evidence for the science and clinical management of cardiovascularkidney-metabolic (CKM) syndrome. 2023. Circulation. 2023; 148(120): 1636–1664.

3. Alberti K.G.M.M., Zimmet P., Shaw J. The metabolic syndrome – a new worldwide definition. Lancet. 2005; 366(949): 1059–1062.

4. Clinical practice guideline for the evaluation and management of chronic kidney disease. Kidney Int. (Suppl.). 2013; 3: 1–150.

5. Levey A.S., Stevens L.A., Schmid C.H., et al. A new equation to estimate glomerular filtration rate. Ann Intern Med. 2009; 150(9): 604–612.

6. Simental-Mendia, L.E., Rodriguez-Moran M., Guerrero-Romero F. The product of fasting glucose and triglycerides as surrogate for identifying insulin resistance in apparently healthy subjects. Metab Syndr Relat Disord. 2008; 6(4): 299–304.

7. Er L.K., Wu S., Chou H.H., et al. Triglyceride glucose-body mass index is a simple and clinically useful surrogate marker for insulin resistance in nondiabetic individuals. PloS One. 2016; 11(3). doi: 10.1371/journal.pone.0149731.

8. Li Y., Gui J., Liu H., et al. Predicting metabolic syndrome by obesityand lipid-related indices in midaged and elderly Chinese. Front Endocrinol. 2023; 14(1). doi: 10.3389/fendo.2023.1201132.

9. Gounden V., Devaraj S., Jialal I. The role of the triglyceride-glucose index as a biomarker of cardio-metabolic syndromes. Lipids Health Dis. 2024; 23(1). doi: 10.1186/s12944-024-02412-6.

10. Zhang S., Du T., Zhang S., et al. The triglyceride and glucose index (TyG) is an effective biomarker to identify nonalcoholic fatty liver disease. Lipids Health Dis. 2017; 16. doi: 10.1186/s12944-017-0409-6.

11. Sun Y., Ji1 H., Sun W., et al. Triglyceride glucose (TyG) index: a promising biomarker for diagnosis and treatment of different diseases. Eur J Int Ned. 2025; 131: 3–14. doi: 10.1016/j.ejim.2024.08.026.

12. Del Pinto R., Viazzi F., Pontremoli R., et al. The URRAH study. Panminerva Med. 2021; 63: 416–423. doi: 10.23736/S0031-0808.21.04357-3.

13. Drapkina O.M., Mazurov V.I., Martynov A.I., et al. Consensus statement on the management of patients with asymptomatic hyperuricemia in general medical practice. Kardiovaskulyarnaya terapiya i profilaktika. 2024; 23(1). doi: 10.15829/1728-8800-2024-3737. (in Russian)

14. Silivonchik N.N., Goloborodko V.I., Lednik A., et al. Assessment of risk factors for the development of non-alcoholic fatty liver disease. Borba s infekcionnymi zabolevaniyami v ramkah realizacii Nacionalnoj programmy demograficheskoj bezopasnosti Respubliki Belarus. Minsk : BelMAPO, 2012: 182–185. (in Russian)

15. Silivontchik N., Adinets D., Vasilieva N., Kachar I. Especially the accumulation of fat in patients with non-alcoholic fatty liver disease. Austria. P. 48.

16. Wood D.A., Kotseva K., Connolly S., et al. Nurse-coordinated multidisciplinary, family-based cardiovascular disease prevention programme (EUROACTION) for patients with coronary heart disease and asymptomatic individuals at high risk of cardiovascular disease. Lancet. 2008; 371(9629): 1999–2012.